S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
The single greatest medical breakthrough of all time? (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
The single greatest medical breakthrough of all time? (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
The single greatest medical breakthrough of all time? (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
The single greatest medical breakthrough of all time? (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
The single greatest medical breakthrough of all time? (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
The single greatest medical breakthrough of all time? (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
The single greatest medical breakthrough of all time? (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
The single greatest medical breakthrough of all time? (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
The single greatest medical breakthrough of all time? (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
The single greatest medical breakthrough of all time? (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
The single greatest medical breakthrough of all time? (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
The single greatest medical breakthrough of all time? (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
OTCMKTS:INNVD

Innovus Pharmaceuticals (INNVD) Stock Forecast, Price & News

$3.00
+1.77 (+143.90%)
(As of 04/11/2019)
Compare
Today's Range
$2.65
$3.49
50-Day Range
$3.00
$3.00
52-Week Range
$1.50
$19.37
Volume
4,300 shs
Average Volume
9,592 shs
Market Capitalization
$7.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

INNVD stock logo

About Innovus Pharmaceuticals (OTCMKTS:INNVD) Stock

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

INNVD Price History

INNVD Stock News Headlines

Inovio Pharmaceuticals Inc. Q2 Loss decreases, beats estimates
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Wall Street Insider Makes Prediction about Hot A.I. Stock
50-year Wall Street Veteran Marc Chaikin just detailed why he's avoiding NVDA and buying this overlooked A.I. stock instead. Learn more here.
Rafarma Pharmaceuticals Inc.
MIST
Inovio Pharmaceuticals Inc. Q4 Loss decreases, but misses estimates
See More Headlines
Receive INNVD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innovus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INNVD Company Calendar

Last Earnings
4/01/2019
Today
8/13/2023

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:INNVD
CIK
N/A
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Net Income
$-8,280,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$23.99 million
Book Value
$0.05 per share

Miscellaneous

Free Float
N/A
Market Cap
$7.07 million
Optionable
Not Optionable
Beta
2.89
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Bassam B. Damaj (Age 51)
    Pres, CEO & Director
  • Mr. Ryan J. Selhorn CPA (Age 37)
    VP & CFO
  • Mr. Randy J. Berholtz (Age 58)
    Exec. VP of Corp. Devel., Gen. Counsel & Sec.
  • Mr. Christopher Stella
    VP of Operations
  • Mr. Robert C. Verfurth
    VP of Sales & Marketing













INNVD Stock - Frequently Asked Questions

How were Innovus Pharmaceuticals' earnings last quarter?

Innovus Pharmaceuticals Inc (OTCMKTS:INNVD) released its quarterly earnings results on Monday, April, 1st. The company reported ($0.99) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.11) by $0.12. The company earned $4.75 million during the quarter, compared to the consensus estimate of $8.13 million. Innovus Pharmaceuticals had a negative net margin of 34.51% and a negative trailing twelve-month return on equity of 682.54%.

What is Innovus Pharmaceuticals' stock symbol?

Innovus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "INNVD."

How do I buy shares of Innovus Pharmaceuticals?

Shares of INNVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Innovus Pharmaceuticals make?

Innovus Pharmaceuticals (OTCMKTS:INNVD) has a market capitalization of $0.00 and generates $23.99 million in revenue each year. The company earns $-8,280,000.00 in net income (profit) each year or ($4.16) on an earnings per share basis.

How can I contact Innovus Pharmaceuticals?

Innovus Pharmaceuticals' mailing address is 8845 Rehco Road, San Diego CA, 92121. The official website for the company is www.innovuspharma.com. The company can be reached via phone at 858-964-5123 or via email at ir@innovuspharma.com.

This page (OTCMKTS:INNVD) was last updated on 8/14/2023 by MarketBeat.com Staff

My Account -